Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Other hematologic neoplasm 2Sarcoma 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Sarcoma, Kaposi 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Maraviroc × Sarcoma × Clear all
NCT01276236 2021-03-05

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

University of California, San Francisco

Phase 2 Completed
13 enrolled 16 charts
Sarcoma

Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡